<>
University of Alberta researchers have developed D-GK17, a stable and nontoxic peptide designed to combat antimicrobial-resistant infections. According to Dr. Prasanna Neelakantan, the peptide targets bacterial and fungal cell surfaces and can break down biofilms, providing a potential alternative to traditional antibiotics that bacteria often learn to resist.
Why is antimicrobial resistance a growing global concern?
Antimicrobial resistance (AMR) represents a significant threat to global health stability. According to the World Health Organization, AMR directly caused approximately 1.27 million deaths in 2019. The organization further reported that AMR contributed to an additional 4.95 million deaths worldwide during that same year.
The threat is amplified by the rise of the “ESKAPE” group of pathogens. These specific bacteria are notorious for their ability to resist standard antibiotic treatments, making common infections increasingly difficult to manage in clinical settings.
Dr. Prasanna Neelakantan, an associate professor at the University of Alberta, described antimicrobial resistance as the “biggest pandemic threatening humanity.” He noted that the medical community requires potent alternatives that bacteria cannot easily bypass through evolutionary resistance.
How does the D-GK17 peptide function against pathogens?
The D-GK17 peptide works by targeting the surfaces of both bacterial and fungal cells. Unlike many existing antimicrobial peptides that can be harmful to human tissue, researchers at the University of Alberta stated that D-GK17 is stable and nontoxic to humans.
While the initial peptide was effective at killing bacteria and fungi, researchers identified a challenge with biofilms. Biofilms are protective layers that microbes build around themselves, making them much harder to eradicate than free-floating cells.
To solve this, the research team created a mirror version of the peptide. According to the study, this version proved capable of breaking down these stubborn biofilms, which are often a primary cause of treatment failure in chronic infections.
What are the potential benefits for wound care?
The development of D-GK17 extends beyond simple pathogen destruction. In skin infection models, researchers observed that the peptide successfully destroyed bacterial biofilms while simultaneously reducing inflammation.
The study also indicated that the peptide promotes wound healing
